Firm recognized for advising Beijing-headquartered Sinovac on funding for COVID-19 vaccine development.
Benjamin Su represents Asia-based clients on cross-border corporate and US securities law matters, particularly involving companies in the technology sector.
Mr. Su leverages more than two decades’ experience navigating global markets and extensive knowledge of US securities law to guide companies and investment banks on:
- US equity and debt registered offerings
- Rule 144A/Regulation S equity and debt offerings and private placements
- Convertible bonds
- Tender offers
- Going-private transactions
- Cross-border mergers and acquisitions
He has worked extensively across the Greater China region, particularly in the technology sector, including semiconductors, electric vehicles, renewable energy, artificial intelligence, fintech, and ecommerce. Mr. Su understands Chinese issuers’ and international underwriters’ commercial objectives in capital markets transactions and crafts responsive, pragmatic solutions.